Медицинская литература. Новинки

 

 

 

 

 

 

РЕШЕНИЕ АКТУАЛЬНЫХ ПРОБЛЕМ ДИАГНОСТИКИ И ЛЕЧЕНИЯ БОЛЕЗНИ ГРЕЙВСА И РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ В РАЗЛИЧНЫХ РЕГИОНАХ МИРА

Вы можете загрузить полный текст статьи в формате pdf

Ключевые слова:

Литература:
1. Волерт В.А. Диффузный токсический зоб у мужчин. Автореф.
дис…канд. мед. наук. СПб., 2002.
2. Гостимский А.В. Хирургическое лечение детей и подростков
с патогенентически разным раком щитовидной железы: Автореф. дис. … дра мед. наук. СПб., 2009.
3. Диагностика и лечение дифференцированного РЩЖ. Клинические рекомендации согласительной комиссии (с небольшими сокращениями). Вестн. хир. им. И.И. Грекова 2008;
67 (3): 59–62.
4. Пирогов Н.И. Хирургический вопрос об экстирпации щитовидной железы. Дерпт,1831. 355–359.
5. Романчишен А.Ф. Клиникопатогенетические варианты новообразований щитовидной железы. СПб.: Наука,1992.
6. Романчишен А.Ф. Хирургия щитовидной и околощитовидных
желез. СПб.:ИПК Вести, 2009.
7. Статистика злокачественных новообразований в России
и странах СНГ в 2007 г. Вестн. РОНЦ им. Н.Н. Блохина 2009;
20(3), прил.1: 11.
8. Ainitaim A., Abouzeid M.E., AlSugair A. et al. No Difference
Whether PETCT is Done While on or Off Thyroxin among
Differentiated Thyroid Cancer (DTC) Patients with High
Thyroglobulin. World Congress on Thyroid Cancer. 2009.
9. Berry J. Diseases of the thyroid gland and their surgical treatment.
London: J. & A. Churchill, 1901.
10. Billroth T. Die Allegmeine chirurgischen pathologie und therapie
in Funfzig vorlesungen. Berlin, 1863.
11. Buchholtz A. wn. E. Bergmann. Berlin, 1913.
12. Carneiro dos Santas A.P., Reis C.F., Vieira C.U. The Antibody
Fragment Library (SCFV) Generated from Well Differentiated
Thyroid Tumors Selected in Thyroid Cells. World Congress on
Thyroid Cancer, 2009.
13. Chnkrabarti A., Joseph S., Ramamurthy S. et al. Role of Neck
Ultrasound Scan to Detect Local Recurrence in Thyroid Cancer
Patients with Undetectable Thyroglobulin Even in the Absence of
Thyroglobulin Antibody. World Congress on Thyroid Cancer,
2009.
14. Cumbronero E., ChenKu C. H., Chinchilla A. et al. Completeness
of Thyroidectomy Based on Postoperative Thyroglobulin Levels
and its Predictive Value. World Congress on Thyroid Cancer, 2009.
15. Сramer J.D., Fu P., Harth K.C. et al. Analysis of the rising incidence of thyroid cancer using thr Surveillance, Epidemiology and
End Results national cancer data registry. Surgery 2010; 148 (6):
1147–1153.
16. Harvard Continuing Education Course “Surgery Thyroid &
Parathyroid Glands” Boston (MA. USA), 2008. November 7–9.
17. Hay J.D. Does Radioiodine Remnant Ablation really “Improve
Outcome” in LowRisk Papillary Cancer Patients, Who have Only
a 1% Risk of Dying from the Disease? World Congress on Thyroid
Cancer, 2009.
18. Ladenson P.W., Singer P.A., Ain K. B. et al. American Thyroid
Association Guidelines for Detection of Thyroid Dysfunction.
Arch. Intern. Med. 2000;. 160: 1573–1575.
19. Lee C. Surgical management of Grave’s disease up-to-date in
Taiwan. 12th Congress of Asian Association of Endocrine
Surgeons, 2010. March 23–24.
20. McCaffrey T.V., Lipton R.J. Thyroid carcinoma invading the upper
aerodigestive system. Laryngoscope 1990; 100: 824.
21. Moss L. UK Survey of Differentiated Thyroid Cancer
Management. World Congress on Thyroid Cancer, 2009.
22. Noguchi H., Uchino S., Yamashita H. et al. Surgical management of
Grave’s disease, past and future. 12th Congress of Asian Association
of Endocrine Surgeons, 2010. March 23–24.
23. O’Toole L. Are We UnderTreating Low Risk Thyroid Cancer
Patients? World Congress on Thyroid Cancer, 2009.
24. Parkyn R.F. Surgical management of Graves’ disease in Australia.
12th Congress of Asian Association of Endocrine Surgeons, 2010.
March 23–24.
25. Pathak K.A. Has the Use of Radioactive Iodine Impacted the
Outcome of High Risk Differentiated Thyroid Cancer. World
Congress on Thyroid Cancer, 2009.
26. Romaldini J.H. Case selection and restrictions recommended to
patients with hyperthyroidism in South America. Thyroid 1997;
7(2): 225–228.
27. Rubino C., Vathaire D., Dottorini M. et al. Second primary malignancy in Thyroid Cancer Patients. Brit. J. Cancer 2003; 89: 1638.
28. Serouya S. “Complete” Total Thyroidectomy is Achievable. World
Congress on Thyroid Cancer, 2009.
29. Sugino K., Ito K., Nagahama M. et al. Surgical management of
Graves’ disease surgical outcome and current policy in our institution. 12th Congress of Asian Association of Endocrine Surgeons,
2010. March 23–24.
30. Tan W.B., Tay C., Tan C. et al. Surgical management of Graves’
disease. Results and changing trend in single institution over
a 19year period. 12th Congress of Asian Association of Endocrine
Surgeons, 2010. March 23–24.
31. Tominaga T., Yokoyama N., Nagataki S. et al. International differences in approaches to 131I therapy for Graves’ disease: case selection and restrictions recommended to patients in Japan, Korea,
and China. Clin. Endocrinol. (Oxf.) 1998; 49(1): 21–28.
32. Vaismnn A., Orlov S., Yip J. et al. Update on the Use of Post-Surgical Stimulated Thyroglobulin in Assisting Radioactive
Remnant Ablation DecisionMaking for Low Risk Well-Differentiated Thyroid Carcinoma. World Congress on Thyroid
Cancer, 2009.
33. Walsh J.P. Management of Graves’ disease in Australia. Aust. N. Z.
J. Med. 2000; 30(5): 559–566.
34. Witt R. What is New in the ATA (American Thyroid Association)
Guidelines// 4th World Congress of International Federation of
Head and Neck Oncologic Societies, 2010

Decision of actual problem of diffuse toxic goiter and thyroid cancer patients treatment and diagnostics in different regions of world

Keywords: